Location History:
- Yamaguchi, JP (2015)
- Ube, JP (2017 - 2019)
Company Filing History:
2 out of 108 
2 out of 1,432 
1 out of 441 
Years Active: 2015-2019
Title: **Hiroyuki Setoguchi: Innovator in Pharmaceutical Chemistry**
Introduction
Hiroyuki Setoguchi is a notable inventor based in Ube, Japan. With a focus on pharmaceutical chemistry, he has made significant contributions to the field with two registered patents. His work centers on the development of novel compounds that demonstrate promising medical applications.
Latest Patents
Setoguchi's latest patents include innovative compounds that target the μ-opioid receptors. The first patent, titled "Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof," describes a crystal composed of a compound that exhibits μ-opioid receptor antagonistic action while minimizing side effects and ensuring high safety. Notably, the crystal boasts high purity and excellent physical properties such as stability and solubility.
The second patent, "3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose," outlines a compound that functions as an antagonist against μ-opioid receptors, emphasizing its safety and minimal side effects. Both patents reflect Setoguchi's commitment to advancing medical treatments through innovative chemical compounds.
Career Highlights
Throughout his career, Setoguchi has been associated with several reputable organizations. He has worked with Sanwa Kagaku Kenkyusho Co., Ltd. and Ube Industries, Inc., where he applied his expertise in pharmaceutical chemistry to drive research initiatives and product development.
Collaborations
Collaboration is vital in the field of innovation, and Setoguchi has worked alongside esteemed colleagues such as Ryo Iwamura and Yasunori Tsuzaki. These partnerships enhance the potential for groundbreaking discoveries and advancements in medical applications.
Conclusion
Hiroyuki Setoguchi exemplifies the spirit of innovation in the pharmaceutical industry. With his groundbreaking patents addressing μ-opioid receptors, he has significantly contributed to the quest for safer medical treatments. His career and collaborations demonstrate the importance of teamwork and shared expertise in advancing scientific knowledge.